semaglutide anti aging recovery Weight-loss drugs 'slow down the ageing process', scientists suggest | Ageing Compounded GLP-1 - Semaglutide &

Predicting outcomes after uvulopalatopharyngoplasty for adult obstructive sleep apnea: a meta-analysis

Clinical trials have demonstrated that patients using semaglutide for weight management typically achieve 1015% body weight reduction over 68 weeks, with most weight loss occurring in the first six months

Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections

Weight loss varies from person to person and depends on factors such as starting weight, treatment duration, nutrition, activity level, and overall health